302 EAST PETTIGREW STREET, DURHAM, NC
Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Prioritizes PBGENE-HBV and PBGENE-DMD Programs for 2026
Precision BioSciences Enters Underwriting Agreement for Stock Offering
Precision BioSciences Presents Phase 1 PBGENE-HBV Data Showing Antiviral Activity
Reports Third Quarter 2025 Financial Results and Provides Business Update
Changes in Board, Management or Compensation
Financial Results, Press Release
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
PRE 14A
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus